Studies have demonstrated the therapeutic effects of SLAB51 on AD, it improves glucose homeostasis, reduces tau phosphorylation [230], increases SCFAs such as acetate, propionate, and butyrate, while decreasing inflammation and Aβ deposition [231]. This evidence concerns the gene MAPT and Alzheimer disease.